Table 1.
Patient information.
| Sample | Gender | Age | Location | M stage | Subtypes |
|---|---|---|---|---|---|
| SNU.AT/RT-1 | M | 13m | Lt. CPA | M3 | MYC |
| SNU.AT/RT-2 | M | 18m | Vermis | M3 | TYR/MYC |
| SNU.AT/RT-3 | F | 32m | Rt. CPA | M0 | MYC |
| SNU.AT/RT-4 | M | 17m | Vermis | M0 | SHH |
| SNU.AT/RT-5 | M | 20m | Lt. LV | M3 | TYR/MYC |
| SNU.AT/RT-6 | F | 2 | Lt. cbll | M0 | TYR/MYC |
| SNU.AT/RT-7 | F | 2m | Rt. cbll | M0 | TYR/MYC |
| SNU.AT/RT-8 | M | 11m | Lt. LV | M3 | TYR/MYC |
| SNU.AT/RT-9 | F | 2m | Rt. cbll | M3 | TYR/MYC |
| SNU.AT/RT-10 | M | 10m | 4V | M0 | TYR |
| SNU.AT/RT-11 | M | 28m | Rt. parietal | M0 | undefined |
| SNU.AT/RT-12 | F | 14m | Rt. CPA | M3 | undefined |
| SNU.AT/RT-13 | M | 23m | Rt. LV | M0 | undefined |
| SNU.MBL-1 | M | 3 | 4V | M3 | Group3 |
| SNU.MBL-2 | F | 3 | 4V | M2 | Group3 |
| SNU.MBL-3 | M | 8 | 4V | M0 | WNT |
| SNU.MBL-4 | F | 7 | 4V | M0 | WNT |
| SNU.MBL-5 | F | 31m | 4V | M3 | Group4 |
| SNU.MBL-6 | M | 7 | 4V | M0 | Group4 |
| SNU.MBL-7 | M | 7 | 4V | M1 | Group4 |
| SNU.MBL-8 | F | 17m | 4V | M0 | SHH |
| SNU.MBL-9 | M | 9m | Lt. cbll | M0 | SHH |
| SNU.MBL-10 | M | 8 | Rt. cbll | M0 | SHH |
| SNU.MBL-11 | F | 4 | 4V | M0 | undefined |
| SNU.MBL-12 | F | 15 | Rt. CPA | M0 | undefined |
| SNU.MBL-13 | M | 11 | 4V | M0 | undefined |
MB, medulloblastoma; AT/RT, atypical teratoid/rhabdoid tumor; M, male; F, female; m, month; Rt, right; Lt, left; V, ventricle; cbll, cerebellum; LV, lateral ventricle.